Osiris Therapeutics, Inc., trading under the symbol OTCMKTS:OSIR, is a biotechnology company focused on the development and commercialization of regenerative medicine products derived from living cells and tissues. Founded in 1992 and headquartered in Columbia, Maryland, the company has positioned itself as a pioneer in adult stem cell science. Osiris applies proprietary processing and preservation techniques to allogeneic cell and tissue therapies aimed at improving patient outcomes in a variety of clinical indications.
The company’s main business activities encompass research, development and manufacturing of cell-based therapies for orthopedics, wound care and surgical applications. Among its marketed products are Grafix, a cryopreserved placental membrane for the treatment of chronic and acute wounds; Stravix, a placental tissue allograft designed for obstetric and surgical use; and Cartiform, an allograft implant intended to repair cartilage lesions in orthopedic patients. Osiris also maintains an active pipeline of investigational therapies targeting conditions such as osteoarthritis, graft-versus-host disease and cardiovascular repair, leveraging mesenchymal stem cell biology to address unmet medical needs.
Osiris operates cGMP processing facilities in the United States and holds regulatory clearances in both the U.S. and Europe. The company collaborates with contract research organizations, academic institutions and government agencies to advance its pipeline through preclinical and clinical stages. These partnerships support Osiris’s efforts to expand its product portfolio and to secure additional regulatory approvals for new indications, reflecting a strategic emphasis on broadening global access to its regenerative therapies.
Corporate governance at Osiris is managed by a board of directors and an experienced executive team with expertise in biotechnology commercialization, cell therapy research and tissue engineering. Under their leadership, the company has achieved multiple regulatory milestones, including FDA clearances and CE markings in Europe. This track record has established Osiris as a notable participant in the growing regenerative medicine sector, with a focus on translating scientific innovation into commercial products that address chronic wounds, orthopedic injuries and surgical repair.
AI Generated. May Contain Errors.
Free OSIR Stock Alerts